"Vitamin D Supplementation and Remission from Chronic Anterior Uveitis" by Hueyjong Shih, Yineng Chen et al.
 

Vitamin D Supplementation and Remission from Chronic Anterior Uveitis

Hueyjong Shih, Department of Ophthalmology and Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
Yineng Chen, Department of Ophthalmology and Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Katie Huynh, Department of Ophthalmology and Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
Eric B. Suhler, Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA.
Jennifer E. Thorne, Wilmer Eye Institute, Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Nirali P. Bhatt, Department of Ophthalmology, The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
C Stephen Foster, Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts, USA.
Douglas A. Jabs, Wilmer Eye Institute, Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Grace A. Levy-Clarke, Department of Ophthalmology and Visual Sciences, West Virginia University, Morgantown, West Virginia, USA.
Robert B. Nussenblatt, Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
James T. Rosenbaum, Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA.
H Nida Sen, Department of Ophthalmology, George Washington University, Washington, District of Columbia, USA.
Sapna S. Gangaputra, Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Abhishek R. Payal, Mahatme Eye Bank Eye Hospital, Nagpur, Maharashtra, India.
Hosne Begum, Wilmer Eye Institute, Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Naira Khachatryan, Department of Ophthalmology, The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sherri-Ann M. Burnett-Bowie, Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Gui-Shuang Ying, Department of Ophthalmology and Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
John H. Kempen, Department of Ophthalmology and Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
Lucia Sobrin, Department of Ophthalmology and Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.

Document Type

Journal Article

Publication Date

11-25-2024

Journal

Ocular immunology and inflammation

DOI

10.1080/09273948.2024.2427857

Keywords

Chronic anterior uveitis; Vitamin D; remission

Abstract

PURPOSE: Chronic anterior uveitis (CAU) often requires suppressive therapy, which has potential side effects including cataract, ocular hypertension, and increased risk of infection. No remittive therapy is currently available; however, several studies have demonstrated an association between low 25-hydroxy Vitamin D (25OHD) levels and either uveitis incidence or uveitis disease activity. This study investigates the potential of Vitamin D supplementation as a remittive treatment for CAU. METHODS: We conducted a retrospective analysis using data from the Systemic Immunosuppressive Therapy for Eye Disease (SITE) cohort study, which included patients with ocular inflammatory disease seen at U.S. tertiary centers between 1979 and 2010. Vitamin D supplementation data was analyzed for patients with CAU. Eyes were considered in remission if they remained quiet for at least 90 days off all anti-inflammatory treatment for eye disease. RESULTS: Among 2688 patients who never used Vitamin D, the cumulative adjusted CAU remission incidence was 13.5% at the 16-month follow-up. In contrast, among 75 patients who used Vitamin D for a duration of ≤1 year, the cumulative adjusted CAU remission incidence was 28% at 16 months. The use of Vitamin D was associated with a crude hazard ratio for remission of 2.14 [95% confidence interval (CI) 1.23-3.71, p = 0.0071], and an adjusted hazard ratio for remission of 2.43 [95% CI: 1.36-4.33, p = 0.0027]. CONCLUSION: In the SITE Cohort, Vitamin D supplementation is associated with a significantly increased incidence of remission. Vitamin D supplementation should be explored in a prospective trial as the next step of evaluation.

Department

Ophthalmology

Link to Full Text

Plum Print visual indicator of research metrics
PlumX Metrics
  • Usage
    • Abstract Views: 3
see details

Share

COinS